Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2016

View Archived Issues

Sun Biopharma reports progress on phase I trial of SBP-101

CASI Pharmaceuticals' phase II trial of ENMD-2076 meets stage I endpoint

Boehringer Ingelheim Pharma patents aldosterone synthase inhibitors

Anthera Pharmaceuticals says phase III SOLUTION trial will continue

Genentech and Constellation Pharmaceuticals disclose TAF1 inhibitors

Genentech and Constellation Pharmaceuticals present KDM1A inhibitors

Neurocrine Biosciences describes antiepileptic agents

Cancer Research UK launches phase I/II trial to evaluate guadecitabine in resistant bladder cancer

Janssen Research & Development gains FDA breakthrough designation for esketamine

NSAID class may be repurposed to treat Alzheimer's disease

Phase III AFFINITY trial of custirsen does not meet the primary endpoint

Vyriad signs license collaboration with Imanis Life Sciences

Xycrobe Therapeutics enters research agreement with Johnson & Johnson

Promising phase III topline results for RBP-6000 monthly depot to treat opioid use disorder

Trek Therapeutics in-licenses rights to Medivir's MIV-802

Evgen receives CTA in U.K. for phase II breast cancer trial of SFX-01

Thalidomide reduces VEGF levels in trial in patients with POEMS syndrome

Eiger initiates phase II trial of pegylated interferon lambda for chronic HDV infection

Oncoceutics Pharmaceuticals wins FDA orphan grant for phase II trial of ONC-201

Japan Tobacco seeks Japanese approval for emtricitabine/tenofovir alafenamide

Study adds to complexity of nasal flu vaccine picture

Pilot study explores use of high-dose thyroid hormone to promote remyelination in MS

Phase II trial explores use of abituzumab in systemic sclerosis-associated interstitial lung disease

Karus Therapeutics initiates phase I trial of KA-2237 in B-cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...